Influence of nucleoside analogue treatment on telomere length and TRF2 amount in human HL60 cells
Author(s) -
X. Liu,
Jian Li,
T. Ogawara,
Yuta Kurashina,
R. Yashi,
Mineo Saneyoshi,
Toshiaki Yamaguchi
Publication year - 2007
Publication title -
nucleic acids symposium series
Language(s) - English
Resource type - Journals
eISSN - 1746-8272
pISSN - 0261-3166
DOI - 10.1093/nass/nrm127
Subject(s) - telomere , guanosine , telomere binding protein , nucleoside , biology , senescence , microbiology and biotechnology , dna , chemistry , genetics , dna binding protein , gene , transcription factor
Long-term treatment with 3'-azido-2',3'-dideoxy-guanosine (AZddG) results in reproducible telomere shortening in cultured human HL60 cells. TRF2 protein has been implicated in the protection of chromosome ends. It binds to double-strand repeats and may have an indirect role in protecting the G-rich overhang by recruiting other telomere-binding proteins to the G-tail or by mediating the formation of the telomeric t-loop. Western blot analysis demonstrated no change or a slight increase, of the TRF2 protein level in HL60 cells with AZddG-induced telomere shortening. The effects of nucleoside analogues on TRF2 suggest that it is not telomere length per se, but rather the presence or absence of a protective telomere state, which determines whether senescence ensues.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom